XML 21 R11.htm IDEA: XBRL DOCUMENT v3.26.1
Cash Equivalents and Marketable Securities
6 Months Ended
Jun. 30, 2026
Cash and Cash Equivalents [Abstract]  
Cash Equivalents and Marketable Securities Cash Equivalents and Marketable Securities
The following is a summary of the Company's investment portfolio as of June 30, 2026 and December 31, 2025 (in thousands):
As of June 30, 2026
Gross UnrealizedEstimated
CostGainsLossesFair Value
Cash equivalents:
Money market funds$79,243 $— $— $79,243 
Available-for-sale securities:
Debt securities issued by U.S. government agencies277,132 — (656)276,476 
Corporate debt securities293,902 — (678)293,224 
Asset backed securities68,267 — (59)68,208 
Commercial paper14,466 — (25)14,441 
Other debt securities247,985 — (1,254)246,731 
Total cash equivalents and marketable securities$980,995 $— $(2,672)$978,323 

As of December 31, 2025
Gross UnrealizedEstimated
CostGainsLossesFair Value
Cash equivalents:
Money market funds$195,296 $— $— $195,296 
Debt securities issued by U.S. government agencies7,003 — (1)7,002 
Available-for-sale securities:
Corporate debt securities198,036 282 — 198,318 
Debt securities issued by U.S. government agencies183,739 258 — 183,997 
Asset backed securities61,282 70 — 61,352 
Commercial paper7,714 — 7,718 
Other debt securities117,424 — (50)117,374 
Total cash equivalents and marketable securities$770,494 $614 $(51)$771,057 
As of June 30, 2026, the Company had 180 securities with a total fair market value of $793.8 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. The Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance was not recognized.
Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):
June 30, 2026December 31, 2025
Within one year$283,790 $242,002 
After one year through five years615,290 326,757 
Total$899,080 $568,759 
Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the three and six months ended June 30, 2026 and 2025.